Pacific Biosciences Of California Inc (PACB) Price Targets From Analysts
| Date | Highest Target Price | Lowest Target Price | Average Target Price | Upside Potential |
| 2022-01-25 | $50 | $20 | $35.166 | 255.93% |
| 2022-02-16 | $50 | $15 | $31.5 | 218.83% |
| 2022-02-17 | $45 | $15 | $25 | 153.04% |
| 2022-02-28 | $45 | $13 | $23.833 | 141.22% |
| High | $27.00 |
|---|---|
| Median | $16.50 |
| Low | $6.00 |
| Average | $15.83 |
| Current Price | $4.33 |
Do analysts agree on Pacific Biosciences of California's (PACs) price targets?
The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $51.67, Pacific Biosciences of California has a forecasted upside of 222.5% from its current price of $16.02.
Where can I buy PACB shares?
Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much did PacBio make in Q4 2021?
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021.
How do I contact PACB?
The biotechnology company can be reached via phone at (650) 521-8000, via email at [email protected], or via fax at 302-636-5454. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
Is Pacb a good stock to buy?
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Why is Pacb stock dropping?
PacBio stock is falling today because the company reported unaudited fourth-quarter revenue that reached just $36 million. Image source: Getty Images. Compared to the prior-year period, revenue soared 33%.
Who bought Pacific Biosciences?
Illumina, Inc.On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019.
What does Pacific Biosciences of California do?
About Pacific Biosciences of California Inc Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
Will Pacb stock go up?
Pacific Biosciences of California Inc (NASDAQ:PACB) The 6 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 16.50, with a high estimate of 27.00 and a low estimate of 6.00. The median estimate represents a +203.03% increase from the last price of 5.45.
What is the stock price of Crispr?
$ 76.09CloseChgChg %$75.82-4.13-5.17%3 days ago
Why did Illumina not buy Pacific Biosciences?
Monopoly Concerns The FTC alleged in an administrative complaint that Illumina was unlawfully seeking to maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by eliminating potential competition from PacBio.
How many employees does Pacific Biosciences have?
Pacific Biosciences corporate office is located in 1305 O'brien Dr, Menlo Park, California, 94025, United States and has 667 employees. pacific biosciences of california , inc.
Is PacBio owned by Illumina?
Illumina is already the biggest player when to comes to DNA sequencing equipment, and an agreement to purchase smaller rival Pacific Biosciences for $1.2 billion tightens its grasp on the market.
What is next generation sequencing technology?
Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA.
What is the difference between PacBio and Illumina?
PacBio provides longer read length than Illumina's short-length reads. Longer reads offer better opportunity for genome assembly, structural variant calling. It is not worse than short reads for calling SNP/indels, quantifying transcripts. Sounds like PacBio can do whatever Illumina platform can offer.
What is Pacific Biosciences sequencing?
PacBio sequencing captures sequence information during the replication process of the target DNA molecule. The template, called a SMRTbell, is a closed, single-stranded circular DNA that is created by ligating hairpin adaptors to both ends of a target double-stranded DNA (dsDNA) molecule (Figure 1) [2].
What is Pacific Biosciences of California's consensus rating and price target?
According to the issued ratings of 4 analysts in the last year, the consensus rating for Pacific Biosciences of California stock is Buy based on th...
Do Wall Street analysts like Pacific Biosciences of California more than its competitors?
Analysts like Pacific Biosciences of California stock more than the stock of other Medical companies. The consensus rating score for Pacific Biosci...
Do MarketBeat users like Pacific Biosciences of California more than its competitors?
MarketBeat users like Pacific Biosciences of California stock more than the stock of other Medical companies. 70.61% of MarketBeat users gave Pacif...
Does Pacific Biosciences of California's stock price have much upside?
According to analysts, Pacific Biosciences of California's stock has a predicted upside of 94.29% based on their 12-month price targets.
What analysts cover Pacific Biosciences of California?
Pacific Biosciences of California has been rated by Cantor Fitzgerald , and Piper Sandler in the past 90 days.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
Over the past 13 months, PACB's average price target has gone up $17.77.
The Trend in the Broker Recommendations
Over the past 122 days, PACB's average broker recommendation rating improved by 0.5.
Stock Price Forecast
The 6 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 21.50, with a high estimate of 40.00 and a low estimate of 15.00. The median estimate represents a +90.94% increase from the last price of 11.26.
Analyst Recommendations
The current consensus among 6 polled investment analysts is to Buy stock in Pacific Biosciences of California Inc. This rating has held steady since January, when it was unchanged from a Buy rating. Move your mouse over past months for detail
When is PacBio conference 2021?
MENLO PARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking at the following investor conferences: Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 am Eastern Time (8:20 am Pacific Time)Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 2:00 pm Eastern Time (11:00 am Pacific Time) The live webcasts can be accessed at the company’s investors page at investor.pacif
When will whole genome sequencing be used?
Whole genome HiFi sequencing will be used on unexplained rare disease cases to evaluate if it can identify variants not readily detectable by short-read sequencingMENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and ARUP Laboratories announced today they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased. ARUP Laboratories has purchas
When will HiFi sequencing be used?
HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencingMENLO PARK, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 02/19/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is fair value in accounting?
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
When is Pacific Biosciences conference call 2021?
(NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: ...
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products.
